RBMXL3 Inhibitors
Chemical inhibitors of RBMXL3 can act through various cellular and molecular mechanisms to hinder its function in RNA processing. Paclitaxel, a microtubule stabilizer, can indirectly suppress RBMXL3 activity by inhibiting cell division, thereby reducing the RNA processing demand within the cell. Similarly, Mitoxantrone and Etoposide, which intercalate with DNA and inhibit topoisomerase II, respectively, can cause DNA strand breaks. This DNA damage can lead to a halt in transcription and consequently a reduction in RBMXL3-mediated RNA processing. Camptothecin, another topoisomerase inhibitor, functions by preventing DNA re-ligation and inducing DNA damage, which can suppress transcription upstream of RBMXL3's functional role. Bortezomib inhibits the proteasome pathway, resulting in a buildup of proteins that can trigger cell cycle arrest and indirectly reduce RBMXL3's involvement in RNA processing due to a general decrease in cell proliferation.
Alpelisib and Sorafenib target the PI3K and RAF/MEK/ERK pathways, respectively, and can suppress cell growth and proliferation. This suppression can lead to an indirect inhibition of the RNA processing activities that RBMXL3 participates in. Axitinib and Ponatinib, both tyrosine kinase inhibitors, can prevent growth factor signaling and cell cycle progression, which in turn can decrease cellular turnover and indirectly limit the RNA splicing and processing roles of RBMXL3. Temsirolimus targets the mTOR pathway, which is crucial for cell growth and division, and can thus indirectly inhibit the processes in which RBMXL3 is involved. Lastly, Venetoclax, which targets the anti-apoptotic protein BCL-2, can induce apoptosis in cells, consequently reducing the overall demand for RNA processing and inadvertently inhibiting the function of RBMXL3. Each of these chemicals can alter specific pathways or cellular processes that, while not directly inhibiting RBMXL3, can lead to a decrease in its functional activity within the cell.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Taxol | 33069-62-4 | sc-201439D sc-201439 sc-201439A sc-201439E sc-201439B sc-201439C | 1 mg 5 mg 25 mg 100 mg 250 mg 1 g | $41.00 $74.00 $221.00 $247.00 $738.00 $1220.00 | 39 | |
Paclitaxel stabilizes microtubules and thereby inhibits their disassembly, which can inhibit cell division. RBMXL3, involved in RNA processing during cell cycle, could be functionally inhibited as cell division is suppressed and the demand for RNA processing is reduced. | ||||||
Mitoxantrone | 65271-80-9 | sc-207888 | 100 mg | $285.00 | 8 | |
Mitoxantrone intercalates into DNA and inhibits topoisomerase II, leading to DNA breaks. As RBMXL3 is involved in RNA splicing, DNA damage might halt transcription and thus indirectly inhibit RBMXL3's RNA processing. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $58.00 $186.00 $94.00 | 21 | |
Camptothecin inhibits topoisomerase I, preventing DNA re-ligation and leading to DNA damage. This can halt transcription upstream of RBMXL3's function in RNA processing, indirectly inhibiting it. | ||||||
Etoposide (VP-16) | 33419-42-0 | sc-3512B sc-3512 sc-3512A | 10 mg 100 mg 500 mg | $51.00 $231.00 $523.00 | 63 | |
Etoposide inhibits topoisomerase II, causing DNA strand breaks. With DNA damage response activation, RNA processing functions including those of RBMXL3 could be indirectly inhibited due to reduced transcription. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib inhibits the 26S proteasome, leading to accumulation of proteins and cell cycle arrest. RBMXL3 function could be indirectly inhibited due to decreased cell proliferation and subsequent RNA processing needs. | ||||||
BYL719 | 1217486-61-7 | sc-391001 sc-391001A sc-391001B sc-391001C sc-391001D sc-391001E | 5 mg 10 mg 50 mg 100 mg 500 mg 1 g | $391.00 $597.00 $755.00 $1192.00 $5000.00 $9370.00 | 2 | |
Alpelisib specifically inhibits PI3K, which is involved in cell survival and growth. By inhibiting PI3K, downstream RNA processing activities linked to cell growth, potentially involving RBMXL3, are indirectly inhibited. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib inhibits multiple tyrosine kinases and the RAF/MEK/ERK pathway, reducing cell proliferation. RBMXL3, associated with RNA processing in cell division, could be indirectly inhibited by reduced proliferation. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib inhibits BCR-ABL and Src family kinases, impacting cell growth and division. Reduced cellular proliferation can indirectly inhibit RBMXL3's function in RNA splicing and processing due to lower cellular turnover. | ||||||
ABT-199 | 1257044-40-8 | sc-472284 sc-472284A sc-472284B sc-472284C sc-472284D | 1 mg 5 mg 10 mg 100 mg 3 g | $118.00 $337.00 $520.00 $832.00 $1632.00 | 10 | |
ABT-199 targets BCL-2, an anti-apoptotic protein, inducing apoptosis in cancer cells. By promoting cell death, RNA processing demand is reduced, which may indirectly inhibit RBMXL3's involvement in RNA splicing. | ||||||
AP 24534 | 943319-70-8 | sc-362710 sc-362710A | 10 mg 50 mg | $175.00 $983.00 | 2 | |
Ponatinib inhibits multiple tyrosine kinases, affecting cell cycle regulation. Inhibition of these signaling pathways can result in reduced cell division, indirectly inhibiting RNA processing functions, including those of RBMXL3. | ||||||